Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure

Discussion The differential effect of fingolimod on the formation of an inflammasome-triggered ASC oligomer in monocytes between responders and nonresponders could be used as a response biomarker after 6 months of fingolimod treatment and suggests that fingolimod may exert their beneficial effects by reducing inflammasome signaling in a subset of patients with MS.

http://nn.neurology.org/cgi/content/short/10/3/e200100?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - March 27, 2023 Category: Neurology Authors: Malhotra, S., Hurtado-Navarro, L., Pappolla, A., Villar, L. M. M., Rio, J., Montalban, X., Pelegrin, P., Comabella, M. Tags: Multiple sclerosis Research Article Source Type: research